M&A Deal Summary

Cephalon Acquires Mepha Pharma Ag

On April 9, 2010, Cephalon acquired life science company Mepha Pharma Ag for 615M USD

Acquisition Highlights
  • This is Cephalon’s 5th transaction in the Life Science sector.
  • This is Cephalon’s largest (disclosed) transaction.
  • This is Cephalon’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2010-04-09
Target Mepha Pharma Ag
Sector Life Science
Buyer(s) Cephalon
Deal Type Add-on Acquisition
Deal Value 615M USD

Target

Mepha Pharma Ag

Aesch, Switzerland
Mepha is a pharmaceutical company developing, manufacturing and marketing branded and non-branded generic products in more than 50 countries. Mepha's R & D organization has developed improved branded generics either through new formulations or using drug delivery technologies, providing additional benefits for healthcare professionals and patients.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Cephalon

Frazer, Pennsylvania, United States
Category Company
Founded 1987
Sector Life Science
Employees3,726
DESCRIPTION

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.

DEAL STATS #
Overall 5 of 7
Sector (Life Science) 5 of 7
Type (Add-on Acquisition) 4 of 6
Country (Switzerland) 1 of 1
Year (2010) 2 of 2
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2010-04-06 Ception Therapeutics

Malvern, Pennsylvania, United States

Ception Therapeutics, Inc. is a emerging biopharmaceutical company which develops novel products to address unmet medical needs.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2011-03-22 Gemin X Biotechnologies

Montreal, Quebec, Canada

Gemin X Biotechnologies Inc. is a biopharmaceutical company that engages in the discovery and development of small molecule cancer therapeutics based on the regulation of apoptosis. The company develops small molecules that target pathways for cancer, including regulators in the genesis and progression of cancer.

Buy $225M
Mergr

Product

Company

Legal